RT Journal Article
SR Electronic
T1 Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.26.20079822
DO 10.1101/2020.04.26.20079822
A1 Asako Doi
A1 Kentaro Iwata
A1 Hirokazu Kuroda
A1 Toshikazu Hasuike
A1 Seiko Nasu
A1 Aya Kanda
A1 Tomomi Nagao
A1 Hiroaki Nishioka
A1 Keisuke Tomii
A1 Takeshi Morimoto
A1 Yasuki Kihara
YR 2020
UL http://medrxiv.org/content/early/2020/05/01/2020.04.26.20079822.abstract
AB Background Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively less number of infections as well as deaths among developed nations. However, accurate prevalence of COVID-19 in Japan remains unknown. Therefore, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.Methods We conducted a cross-sectional serologic testing for SARS-CoV-2 antibody using 1,000 samples from patients at outpatient settings who visited the clinic from March 31 to April 7, 2020, stratified by the decade of age and sex.Results There were 33 positive IgG among 1,000 serum samples (3.3%, 95%CI: 2.3-4.6%). By applying this figure to the census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934-69,868). Age and sex adjusted prevalence of positivity was calculated 2.7% (95%CI: 1.8-3.9%), and the estimated number of people with positive IgG was 40,999 (95%CI: 27,333-59,221). These numbers were 396 to 858 fold more than confirmed cases with PCR testing in Kobe City.Conclusions Our cross-sectional serological study suggests that the number of people with seropositive for SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was conducted using unrestricted research funds of Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, provided by Tsumura & Co. and Takasago Seibu Hospital.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request.